A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or
HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a
treatment for AIDS. Patients with documented HIV viremia will be evaluated. Effects on virus
replication, immune function, and clinical condition will be monitored with periodic virus
cultures, estimates of lymphocyte type and numbers, cell surface markers, in vitro lymphocyte
responses and frequent clinical evaluations.